Skip to main content

Kymera Therapeutics, Inc.

KYMR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001815442

In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.

Members of Congress who traded KYMR

No member of Congress has reported a trade in Kymera Therapeutics, Inc. since 2020.

Source: U.S. House Clerk and Senate Office of Public Records (eFD). Amounts are the ranges filers report.